-Case Reports-

Safety of Abiraterone Acetate Administration in Elderly Patients Receiving Peritoneal Dialysis with Castration-Resistant Prostate Cancer: Two Case Reports

Ryoji Kimata¹, Yuji Tomita¹ and Yukihiro Kondo²

¹Department of Urology, Nippon Medical School Musashi Kosugi Hospital, Kanagawa, Japan
²Department of Urology, Nippon Medical School, Tokyo, Japan

We report two elderly patients receiving peritoneal dialysis with castration-resistant prostate cancer (CRPC). Herein, we show that the patients were safely treated using abiraterone acetate (750 mg/day orally once daily) and prednisolone (5 mg/day orally once daily). Although the prostate-specific antigen (PSA) level increased in both cases, there was no manifestation of disease progression (clinical and radiographic) for 22 months in case 1 and 8 months in case 2. In case 2, the only adverse event was hypokalemia, which was treated using potassium preparations.

J Nippon Med Sch 2019; 86: 135-138

Keywords
castration-resistant prostate cancer, abiraterone acetate, peritoneal dialysis

Correspondence to
Ryoji Kimata, MD, PhD, Department of Urology, Nippon Medical School Musashi Kosugi Hospital, 1-396 Kosugi-cho, Nakahara-ku, Kawasaki, Kanagawa 211-8533, Japan
s2027@nms.ac.jp

Received, November 8, 2018
Accepted, December 10, 2018